Senescent Cell Targeting Shows Promise for Treating Age-Related Lung Diseases

Cellular senescence represents a critical mechanism underlying lung aging and age-related pulmonary diseases. This comprehensive review by Ozdemir and colleagues provides an in-depth analysis of how senescent cells contribute to lung pathology and explores emerging therapeutic strategies to target these cells.

The authors examine the molecular mechanisms driving cellular senescence, including DNA damage response pathways (p53/p21, p16INK4a/RB), mTOR signaling, and p38 MAPK activation. They detail how different types of senescence - replicative, stress-induced, oncogene-induced, and therapy-induced - each contribute uniquely to lung disease progression. Particularly important is the senescence-associated secretory phenotype (SASP), which includes inflammatory cytokines, chemokines, and growth factors that promote chronic inflammation and tissue dysfunction.

The review highlights significant heterogeneity among senescent cell populations in the lung, affecting various cell types including alveolar epithelial cells, fibroblasts, and endothelial cells. This cellular diversity creates distinct 'senotypes' with different SASP profiles and functional consequences. In diseases like COPD and idiopathic pulmonary fibrosis, senescent cells lose regenerative capacity while secreting factors that sustain inflammation and promote fibrotic remodeling.

Two main therapeutic approaches show promise: senolytics, which selectively eliminate senescent cells through targeted apoptosis, and senomorphics (senostatics), which suppress harmful SASP effects without removing the cells. Natural compounds like quercetin, fisetin, and resveratrol, along with repurposed drugs including dasatinib, navitoclax, metformin, and rapamycin, are currently in clinical trials. Novel approaches under development include HSP90 inhibitors, senolytic CAR-T cells, and targeted drug delivery systems.

The authors emphasize that successful translation of senotherapeutics faces challenges including cellular heterogeneity, drug delivery specificity, long-term safety concerns, and the need for robust biomarkers to identify senescent cell populations. Future directions point toward personalized medicine approaches and combination therapies tailored to specific senescent cell subtypes and disease contexts.